
Inam Ur Rehman
About Inam Ur Rehman
Data last updated:
Inam Ur Rehman has 23 years in corporate governance. Holds Director role. Currently with 2 companies, including Cellopharma Research Private Limited and Ravenbhel Health Care Private Limited. Engaged in General Business, Healthcare. Contributes to corporate operations. The largest current company by reported revenue is Ravenbhel Health Care Private Limited at ₹291 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 06 Jun 2003 | 2003 | ₹291 Cr (FY 2025) | Active | |
| Director | 18 Oct 2025 | 2025 | – | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Inam Ur Rehman
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inam Ur Rehman
Inam Ur Rehman has 23 years in corporate governance. Holds Director role. Currently with 2 companies, including Cellopharma Research Private Limited and Ravenbhel Health Care Private Limited. Engaged in General Business, Healthcare. Contributes to corporate operations. The largest current company by reported revenue is Ravenbhel Health Care Private Limited at ₹291 Cr (FY 2025).
Inam Ur Rehman is associated with 2 companies as Director, including Ravenbhel Health Care Private Limited (₹291 Cr), Cellopharma Research Private Limited.
Inam Ur Rehman has expertise in General Business, Healthcare.
Inam Ur Rehman has 23 years in corporate governance.
By reported revenue, the largest current company of Inam Ur Rehman is Ravenbhel Health Care Private Limited, with revenue of ₹291 Cr (FY 2025).
Inam Ur Rehman currently holds positions at 2 companies: Ravenbhel Health Care Private Limited (₹291 Cr), Cellopharma Research Private Limited.